Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427
Status:
Recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo controlled, study will be conducted to evaluate the
safety, tolerability, and pharmacokinetics of ST-2427. Subjects will be randomized to receive
a single dose of ST-2427 or placebo in a Single Ascending Dose (SAD) design.
A total of 30 subjects will be enrolled. Subjects will be randomized in a 4:2 ratio of
ST-2427 to placebo. Study drug will be blinded to all subjects and investigators.